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The case company of this study is Shanghai Xin-xing Medicine Co. Ltd., the subsidiary of 
China General Technology Group in Shanghai City of China. The company manufactures 
plasma products. This study gives information about the company, their products and the 
outlook of marketing Chinese plasma products in Finland. 
The goal of the study is to clarify the method of marketing Chinese plasma products in 
Finland. For that purpose one survey-questionnaire was sent to 20 main hospitals in 
different areas in Finland and two interviews with Finnish Red Cross Blood Services and 
Shanghai Xin-xing Medicine Co. Ltd. 5 hospitals gave responses to the questionnaire, the 
return rate turned out to be 25% as 5 responses to the questionnaire were received. 
The analysis of the results from the questionnaire and the information from the interviews 
manifest that the market demand of plasma products in Finland keeps growing and there 
is potential market for Chinese plasma products, yet the company cannot expand into the 
Finnish market now, due to the lack of the EU-GMP (Good Manufacturing Practice) 
certificate.  
Based on those information, a WHO-GMP or EU-GMP certificate is crucial to the 
company as to facilitate the process of achieving the potential Finnish market by 
establishing more stations of sole plasma collection to maintain sufficient raw material 
plasma, so that it would achieve the potential Finnish market in future years 
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1. INTRODUCTION 
When a company plans to expand to a new foreign market, there are many factors 
that should be taken into consideration before entering the market. There are two 
main factors which influence this process of clarifying the way to marketing; one is 
if the product meets market demand, another one is a suitable distribution channel 
between the company and the target market. (Ogenyi Omar; International market; 
P153, Entry as international marketing strategy) 
The aim of this study is to find out the method of marketing Chinese plasma 
products in Finland. The introduction part will present the background of this 
research, pointing out the considerations for choosing this subject. Furthermore, a 
brief introduction to the theoretical background and the research methodology, 
together with an explanation of the objective, research questions, and limitations of 
this study are presented. 
The products, including the plasma products, are manufactured in China with low 
cost but high quality. Nowadays, with the speedy growth of economy of the country, 
plasma products industry in China has developed very quickly. China is one of the 
few developing countries that manufacture plasma products 
Rapid economic development, population aging, expansion of disease, as well as 
the improvement of product safety will promote rapid growth of plasma product 
industry. The leading enterprises with financial and technical advantages of 
expansion will further increase industry concentration. 
Nowadays, major market of blood products are still the United States and Europe, 
but the imports and exports of albumin and coagulation factor VIII from China, 
Brazil and other developing countries have been the main engine of growth in the 
past few years. 
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As one of the European Union members, Finland earns an image of high welfare 
country. Finnish government spends a lot of money on the healthcare system and 
institutions annually. Although Finland has a high tax rate charge for the imported 
goods, it still maintains high profit for the sellers, especially for the enterprises 
which expand their business area in Europe, therefore Finland is a crucial market. 
1.1 Objective 
The client for the study is Shanghai Xin-xing Medicine Co. Ltd. (Sxx Company), 
manufacturer of plasma products. The company is located in Shanghai City China. 
Company is the subordinate, subordinating to the company of China General 
Technology (Group) Holding, Ltd. 
The purpose of this study is to clarify the method of marketing Chinese plasma 
products in Finland. 
1.2 Research methodology 
The research approach in the thesis is written combination based on the 
quantitative methods but there is qualitative method used in the study as well. The 
research is a trend analysis, mainly based on the fact of the results got from the 
hospitals and interview of director from Finnish Red Cross Blood Services in 
Finland and the manager from Shanghai Xin-xing Medicine Co. Ltd. 
The main research methodology is survey-questionnaire. The research is to 
illustrate the present situation of the market and method of marketing Chinese 
plasma products in Finnish market as well. 
The method of data collection is as an implementation tool for quantitative 
approach. With respect on the thesis research, the essential data can be found 
from the sources which are collected throughout the research questionnaire, and 
also internet sources for relevant knowledge of plasma product industry.  
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1.3 Thesis structure 
There are two main parts of the research study: the theoretical part and the 
empirical part. The theoretical part deals with information given by the company, 
Finnish economy and international market adapting 4Ps, about distribution 
channel between Shanghai Xin-xing Medicine Co. Ltd. and Finnish medical 
institutions. 
First, the introduction of general information about the Shanghai Xin-xing Medicine 
Co. Ltd. and the holding group will be presented. Then a thorough analysis about 
the Finnish economy and market, as well as Finnish healthcare will be introduced. 
The last part of theoretical study deals with the distribution channel of plasma 
product. 
4Ps study and SWOT analysis are conducted in this study. It will make a clear 
understanding both for micro and macro environment in Finnish market. 
Environmental factors analysis is used for analyze the method of marketing the 
products. 
The empirical study is based on the questionnaire that was sent to 20 main 
hospitals in Finland, the e-mail interview with the Finnish Red Cross Blood 
Services and telephone interview with the vice manager of the case company. 
With the analyzing of the outcomes of the survey-questionnaire, some charts have 
been made. Conclusions will show the recent situation of the market for plasma 
products and how Chinese plasma products are going to adapt market in Finland. 
Summary concerning the whole research are given in the end of the thesis. 
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2. INFORMATION OF PLASMA PRODUCTS 
2.1 Plasma products 
The plasma product is in the scope of biological products, which take the plasma 
collected from healthy people as raw material, through using biological processes 
or biological purification technology to get the bioactive preparation. It is widely 
used in clinical rescue and treatment, Plasma product is an important life-saving 
medicine. 
Nowadays, approximately 20 different kinds of plasma products have been used in 
clinical medicine, such as human serum albumin, human placental serum albumin, 
intravenous immune globulin employment, intramuscular human immunoglobulin, 
histamine, human immune globulin, specific immune globulin, hepatitis B immune 
globulin, rabies immune globulin, tetanus immune globulin, human coagulation 
factor Ⅷ, human prothrombin complex, fibrinogen, and anti-human lymphocyte 
immune globulin. And there are some other new products under the R&D process, 
such as Freeze-dried human thrombin, S/D-FFP, anti-thrombin- Ⅲ , topical 
lyophilized human fibrin glue ect. 
Illustration of different types of plasma products: 
ClassⅠ: Albumins Products 
It usually refers to a concentration of 20 ~ 25g/dl albumin products. Mainly used to 
correct for major surgery, trauma, organ transplantation due to acute hypovolemia; 
processe body fluids of water, electrolyte and colloid imbalance caused by large 
area burn and respiratory distress, prevent and control shock.; hypoproteinemia, 
etc. 
 
 
8 
 
ClassⅡ: Immunoglobulin products 
Normal human immunoglobulin: mainly used for certain viral diseases, such as 
hepatitis A and measles prevention of disease. 
Specific immunoglobulin: compared with normal immune globulin, it has the 
advantages of more reliable protective effects, and some also have a definite 
therapeutic effect. 
Intravenous immunoglobulin products: a better use of high dose intravenous 
tolerance, with an increase in the production process viral inactivation steps to 
improve the safety, and clinical indications continue to increase. These kind of 
products which now are the leading products in plasma products industry have 
been increasingly widely applied. 
Class Ⅲ: Coagulation factor type products 
Fibrin sealant: used in plastic surgery, micro surgery, neurosurgery and other fields. 
The products in the production are processed by the viral inactivation treatment, 
and increased use of security. 
Factor Ⅷ products: It is for the treatment of hemophilia. Specific activity was 0.2 ~ 
1.0IU/mg protein and> 10IU/mg protein in the middle purity and high purity factor 
Ⅷ products. Not only small size, high titer, easy home use, but also because of 
higher purity, combined with the production process Virus inactivation was carried 
out, so that fewer adverse reactions are in use and it is more secure. 
(Research Report of Produce and Sale and Investment Analysis on China Blood 
Products Industry 2008; P22-P23 the definition of plasma product) 
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PICTURE 1. THE PLASMA PRODUCTS 
Plasma products from Sxx Company are shown in the picture above. The products 
are stored in glass bottles in low temperature environment and used for clinical 
injection. 
2.2 Plasma products industry in China 
In recent years, production of blood products in China has been developing rapidly, 
and production changes from single species to varieties. Comprehensive 
utilization of raw material plasma rises up steadily. 
33 Chinese manufacturers of blood products have obtained GMP certification 
(Good Manufacturing Practice), with the annual plasma volume of around 3,500 
tons totally. Now there are 9 plasma products recorded in the Chinese 
Pharmacopoeia. Among the 33 manufacturing companies, 23 of them can produce 
more than 4 types of those 9 products. 
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From January to August of 2010, human serum albumin, intravenous human 
immunoglobulin, tetanus human immunoglobulin, hepatitis B immunoglobulin, 
human immunoglobulin, human prothrombin complex, rabies immunoglobulin and 
human clotting Factor VIII of Hualan Biological Engineering Ltd were approved by 
National Institute for the Control of Pharmaceutical and Biological Products, with 
the total release volume of 2.272 million bottles. (Chinese Blood Products Industry 
Report 2010, Summary) 
The Chinese government attaches great importance to the development of blood 
products industry, especially the National Development and Reform Commission in 
a timely manner in accordance with market demand and supply. To adjust product 
prices, government has played an active role in keeping the blood products to 
maintain a reasonable value, and the protection of clinical drug supply. However, 
considering the late start in China blood product industry, the scale is limited. The 
industry is still facing many difficulties that hinder its development. (Research 
Report of Produce and Sale and Investment Analysis on Chinese Blood Products 
Industry 2008; P54 Blood products industry profiles) 
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3. SHANGHAI XINXING MEDICINE CO. LTD. 
Sxx Company is a nationally significant high tech enterprise which advanced in the 
R&D, manufacturing and distribution of blood products. The corporation was 
founded in August 2000 with registered capital of 164 million YUAN RMB. It is a 
joint-stock company, LTD and non-listed. 
The predecessor of Shanghai Xin-xing Medicine LTD., CO is Shanghai S&T 
development center for health care products, which was founded with a loan of 50 
thousand YUAN RMB given by the government in 1989. 
The company is a fast growing enterprise. With the development strategy of 
establishing a modern blood products industry, the company owns the advanced 
techniques, good manufacturing conditions and flowing trade channels. Through 
the capital accumulation from distribution, business expansion by high technology, 
the company has become a national famous blood products manufacturer since 
the shareholding reform in 2000. 
After the shareholding reform, the company owned outstanding achievements in 
distribution and thus accelerated the growing speed. Till 2005, the company 
realized more than 1 billion YUAN RMB of distribution, 76 million YUAN RMB of 
total profits, 450 million of total assets which were increased 8 thousand times of 
the founded period. In terms of Scale of production it ranks No. 4 in the whole 
blood products industry in China. 
Company is a modernization plasma products manufacturer which owns the 
advanced techniques, good manufacturing conditions and flowing trade channels. 
Shanghai Xin-xing Medicine Co. Ltd. holds the specialized techniques for 
comprehensive utility of plasma and smart properties for virus inactivated. And 
also it has a research team with great power. The research speed of new products 
is very fast. 
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The company has been evaluated as one of the nationally significant high tech 
enterprises, Shanghai high tech industry and technical development institute in 
PUDONG area for several years. The company was approved to set up 
postdoctoral workstation by national government. 
 
PICTURE. 2 MAIN PRODUCTS OF SXX COMPANY (NATIONAL MAJOR 
PRODUCTS) 
The corporation’s main products include human serum albumin, prothrombin 
complex, fibrin sealant, and hepatitis B immunoglobulin which were successively 
chosen to be national major products, Shanghai high tech production 
transformation projects, Shanghai and national torch projects respectively. 
(Shanghai Xin-xing medicine co. Ltd. official website; Profile, About Xin-xing [ref. 
2nd August 2011]) 
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PICTURE 3. SHANGHAI XINXING MEDICINE CO. LTD. 
Now the company has 2 subsidiary stations of sole plasma collection which collect 
the raw material-plasma for the company’s production. These 2 plasma collection 
stations can approximately provide totally 60 tons of plasma annually. (Shanghai 
Xin-xing medicine co. Ltd. official website; Profile, About Xin-xing, Subsidiary 
stations of sole plasma collection [ref. 2nd August 2011]) 
Shanghai Xin-xing Medicine Co. Ltd. invested 170 million YUAN RMB to establish 
the advanced workshop which was certificated by Good manufacturing practice 
(GMP), and the roboticized and systematized production line with the production 
capacity of 300~500 tons every year. We also owned drug distribution headquarter 
which was certificated by GSP (Good Supply Practice). The distribution network 
covers the whole country and expands to Pakistan, Bulgaria, Thailand and 
Indonesia and some Eastern-euro countries. (Shanghai Xin-xing medicine co. Ltd. 
official website; Profile, About Xin-xing [ref. 2nd August 2011]) 
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3.1 China General Technology (Group) Holding, Ltd. 
China General Technology (Genertec) Group is set up on the basis of 6 
professional foreign trade companies in different business area. Pharmaceutical 
industry, trade & engineering contracting, equipment manufacturing, technical 
services and consultancy, and also the construction and real estate. 
Most of these large foreign trade enterprises have 50 years of operating history, 
since the establishment of the group, their import and export volume totaled more 
than $ 200 billion. With the major equipment and advanced technology, the 
Genertec group has become one of the biggest and most important national group 
in China. 
 
FIGURE 1. RELATIONSHIP OF THE COMPANY AND THE GROUP 
The group is currently the largest in draught of bidding, technical service providers, 
China's major large-scale and complete equipment export, international project 
contracting, and external economic and technical cooperation enterprises. And it 
has the largest foreign trade enterprise with medicine and health products 
business. 
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General Technology Group has been established with the main operating 
indicators maintaining a steady growth. A state-owned asset has always been 
outstanding in the industry level. In the year 2007, the Group achieved operating 
income of 13.9 billion Yuan RMB, incremental value rate 117.4 percent and total 
assets of 216 billion Yuan RMB. 
After 50 years’ efforts, the Group has business partners worldwide and 
comprehensive business channels. It formed a strong business, expanded 
capacity and coverage of major domestic markets and overseas global business 
networks. The company created an excellent brand and reputation and also 
trained a staff team which is familiar with international trade rules, business 
experience. Asset of the company is very good, and investment and financing 
ability is strong as well. The financial sector in domestic and international market 
has a good credibility. 
The group has established stable trade and cooperation relations with more than 
100 countries and regions across the world. 
(China General Technology (Group) official website; About Us > Corporate Profile 
[ref. 4th August 2011]) 
 
3.2 The production of the company 
Plasma product is the variety special functional proteins separated and purified out 
from raw material plasma. It contains hundreds of plasma proteins in the blood. 
The main contents are albumin (Albumin) and gamma globulin (Im2mune 
Globulin), and the residual is the trace protein. The company has been able to 
produce the albumin, gamma globulin, prothrombin complex concentrate (PCC), 
FVIII factor, fibrinogen and fibrin glue and other products.  
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With the people's living standards improving and expanding need of blood 
products for the clinical application, it presents a situation of shortage supply of 
plasma products. 
As the raw materials are directly collected from human plasma, although there is a 
rigorous screening for the donors, there are still known or unknown virus risks. For 
risk reduction, company imported foreign advanced technology and equipment for 
plasma collection and manufacturing as well. After that, company worked out a 
practical plasma testing scheme to make sure the raw material is safe enough. 
Control examination of donors’ plasma: 
1. Measurement of haemoglobin concentration; 2. Determine total serum protein 
not less 60g/L; 3. Test for HbsAg, should be negative; 4. Test for anti-HIV, should 
be negative; 5. Test for anti HCV, should be negative; 6. Test for syphilis, should be 
negative; 7. Serological test for syphilis should be negative. 
 
PICTURE 4. COLLECTING SYSTEM: PCS2 COLLECTING SYSTEM 
For control the safety of collected plasma, Sxx Company follows the examination 
steps mentioned in last paragraph. The collecting system which is made in the 
USA shown in the picture above is used to exam the plasma step by step. 
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The company has a post-doctoral research station and Asia first-class blood 
products manufacturing plant. With GMP certificate from State Food and Drug 
Administration (SFDA) China, the strength of the company is in R&D and 
advanced production technology. 
Most of the production equipment now being used are imported from Germany, 
America, and Italy. Multi-effect water & pure Steam Generator is made in Finland. 
The company has a stable relationship with all the equipment suppliers, and it is 
good for the company to get the latest equipment with the updated information. 
This is the basic condition to keep the production with an efficient performance. In 
the year 2010, company invested 26.5 million Yuan RMB to upgrade the 
production workshop, so that it can meet the latest requirements of the Ministry of 
Health and get the newest GMP certificate. 
 
FIGURE 2. MAIN EQUIPMENTS FOR MANUFACTURING 
Based on the advanced production equipment, combining the technology from the 
high performance R&D department, the company now can manufacture 10 kinds 
of high quality plasma products, which ranks second in this industry in China with 
product varieties. 
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Every year, Sxx Company invests about 20 million Yuan RMB to the R&D program 
to keep the company stay in an advanced position in R&D in the same industry. At 
present, the company has 3 new products under research, they are Human 
Coagulation Factor Ⅷ , Recombinant Human Coagulation Ⅶ  for Injection and 
Alpha-1-Antitrypsin Reagents. (Introduction of Shanghai Xin-xing Medicine Co. Ltd. 
English version, P9-P18) 
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4. THE 4PS ANALYSIS AND SWOT ANALYSIS 
Mostly there are some uncontrollable factors and controllable factors that affect the 
effectiveness of marketing activities of the enterprise. The Social / demographic, 
Technological, Economic, Environmental / Natural, Political, Legal, Ethical, 
Geographical Factor and other environmental factors, known as uncontrollable 
factors, which is the external environment faced by the enterprises. Another one is 
the factor company can control, such as product, price, place, promotion and other 
marketing factors, known as enterprise controllable factors. 
"If the company produces the right products, set an appropriate price, use 
appropriate distribution channels and is supported by appropriate promotional 
activities, then the company will be successful." Said Philip Kotler in 2001. 
The essence of enterprise’s marketing activities is the process to adapting the 
external environment within a controllable internal factor, by planning and 
implementation of product, price, place and promotion to make a positive dynamic 
response for external uncontrollable factors, thus contributing to the business 
achievement and satisfy individual or organizational goals. ([U.S.] Philip Kotler, 
marketing management (11th edition) [M], P8, Chapter 1) 
4Ps are described in the following text mostly from Chinese market point of view, 
the situation of international market and also Finnish market are introduced as well. 
4.1 Product 
A normal product is tangible, physical entity that they can be buying or selling, but 
if you consider more deeply, there are actually three level of one product - the 
CORE product, the ACTUAL product, and finally the AUGMENTED product. 
The core product is the part you can’t touch or see, which refer to the benefit of the 
product that makes it valuable, plasma products as the medicine, it must be 
effective and it has to heal the disease. That is the value of it.  
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The actual product is the product you can see and touch, which can be used for 
some purpose. For plasma products, they are used for injection and infusion, 
which get into your body.  
The augmented product means the added value of the products. After you use 
plasma products, the doctor will follow the consequent, if there is something wrong, 
they can give feedback to the manufacturer who is responsible for solving the 
problem. So it can also be understood as the after-sale services. 
(Marketing lessons, three level of a product [ref 8th, November 2011]) 
Sxx Company ranks second in the China with products varieties, which means the 
company can manufacture 10 kinds of plasma products at present. 3 new products 
are under research; new products will get into the market in the following 2-5 years 
to match the increasing market demand. 
Leading products: human serum albumin (mainly used to increase blood volume, 
maintain the plasma colloid osmotic pressure, transport and supply nutrition); 
human immune globulin (used to treat the indication of immunoglobulin deficiency); 
human prothrombin complex (used to treat the indication of factor II, VII, IX, X 
deficiency). 
Products with manufacture and distribution permission: human fabric sealant 
(used to conglutinate, protect the wounds and stop bleeding); intramuscular 
injection human hepatitis B immunoglobulin (used to prevent hepatitis B). 
In addition, now there are 3 new products under research, which will be put into 
production in the following years. At that time, they can make more profits for Sxx 
Company. 
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The first product is Human Coagulation Factor Ⅷ which is used for treatment of A 
type of hemophilia. In 2009 the company obtained clinical approval number and 
completed clinical trials by 2010, and it’s going to obtain production approval 
number in 2012.  The cost of R&D for this product is 3 million Yuan RMB annually, 
after it is put into the market, it can make approximately 8 million Yuan/year net 
profit. 
The second one is Recombinant Human Coagulation Ⅶ for Injection which is used 
for hemophilia treatment. During 2010-2013 the preliminary R&D work will be done. 
In the 2013-2014 test data files will be ready to apply for clinical documents of 
approval, and in the 2014-2017 it will apply for clinical approval documents to 
complete clinical trials, and implementation of product released. The investment of 
this project is 8-10 million Yuan RMB, and it will achieve about 8 million Yuan/year 
net profit. 
 The Last one is Alpha-1-Antitrypsin Reagents which is used for the treatment of 
emphysema. Company invests 5.311 million Yuan RMB in this product with the 
expectation of 6 million Yuan/year net profit. Application of clinical approval 
number will be done in 2012, in the year 2014 to obtain approval of clinical trials, in 
order to carry out clinical trials in 2015. 
 (Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year Development Plan, P17) 
4.2 Price 
Depending on market positioning, develop different pricing strategies, the product 
pricing of the company is based on corporate brand strategy, focusing on the value 
of brand. 
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According to the position of competitors’ existing products on the market, the 
company targeted the degree of attention of customers to the products 
characteristics or attributes, creating the deep impression of a distinctive and 
unique image for enterprise products. By vividly passing this image to the 
customers, so that it is left to the products to determine the appropriate position in 
the market. 
Pricing objective of the company is to be as the active instrument of completing 
marketing objectives, which is the ensuring and means to achieve the overall goal 
of the business. (Philip r. Cateora; Mary c. Gilly; John l. Graham, International 
marketing (14th edition); P528, Pricing Objectives) 
Price elasticity of demand in economics generally used to measure the changes of 
demand with the changes in commodity prices. 
Suppose Q is a demand for goods, P stands for the price, the price elasticity of 
demand is calculated as Ed. 
 
When Ed = 0: perfectly inelastic 
When 0 <Ed <1: lack of flexibility, not elastic or inelastic (inelastic) 
When Ed = 1: unit elastic, unitary elastic, or an elastic constant (unit elasticity) 
When: flexible 
When: fully flexible or fully flexible (perfect elasticity) 
Therefore plasma product is considered to be inelastic. Under normal 
circumstances, plasma product has been treated as necessities of life as 
indispensable, a small amount of the price change will not cause drastic changes 
in market demand. (Price elasticity of demand calculation method website) 
Now company is using two pricing methods: Cost-driven pricing and Competition-
driven pricing. They can be used both in domestic and overseas market. 
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Cost-driven Pricing takes product unit-cost as the basis, compared with the market 
price and considers the interests of shareholders to determine the price. The price 
may change flexibly with the fluctuation of manufacturing cost and market 
composite price. It is the most commonly used pricing method of the company. 
Because the actual situation of limited collection of raw material plasma, so the 
volume of sales can be calculated. Under this condition, the company uses 
breakeven pricing to give the price, which means in the condition of fixed sales, 
the price of enterprise products must meet certain standards in order to achieve 
break-even point to keep profit and loss in balance. 
Competition-driven Pricing is through studying Production conditions, service 
conditions, prices and other factors of competitors, according to company’s 
competitive strength, cost and supply and demand to identify prices. 
Today's blood products industry is highly competitive; any enterprise cannot 
achieve an absolute advantage by its own strength in the market. In order to avoid 
the losses caused by competition, especially price competition, company has 
adopted to follow the going-rate pricing. The company will maintain a price level of 
the average market price to get the average price paid. 
In addition, using going-rate pricing, company doesn’t need to fully understand the 
consumers' reactions to different price, and will not cause price fluctuations. 
(Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year Development Plan; P15-P17) 
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 Standards Prices 
 
Human serum albumin 10 g / bottle 310 Yuan RMB 
Intravenous immunoglobulin 
 
2.5 g / bottle 470 Yuan RMB 
Human prothrombin complex 
 
300 units / bottle 212 Yuan RMB 
 
Human fibrinogen 0.5 g / bottle 150 Yuan RMB 
intramuscular injection human 
hepatitis B immunoglobulin 200 units / bottle 200 Yuan RMB 
Human clotting factor VIII 
 
200 units / bottle 400 Yuan RMB 
100 Yuan RMB= 11.75 EUR（23.11.2011） 
FIGURE 3. PRICES OF MAIN PRODUCTS 
The data from the above figure shows the manufacturing cost of the main products 
of the company in China. Cost also is the basic reference when considering pricing 
in Finnish market. 
When the company considers exporting products to Finland, there are many other 
things which need to be taken into consideration, such as the inflation, taxes, 
tariffs, exchange rate fluctuation, transport cost and so on. (Philip r. Cateora; Mary 
c. Gilly; John l. Graham, International marketing; P535 Price Escalation) 
Consider the current situation of distribution of plasma products in Finland are 
most through the FRCBS, so the company may consider administered pricing. It is 
an attempt to make prices for the entire market, and always arranged through 
national, state government or international agreement. (Philip r. Cateora; Mary c. 
Gilly; John l. Graham, International marketing; P551 Administered Pricing) 
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4.3 Place 
As the uniqueness of plasma products, the company does not directly face the 
final customers which are the patients. They usually focus on the cultivation of the 
distributor and the establishment of sale network. The contact of company with 
consumers can be carried out through distributors. 
The company now has primarily established the distribution system all around 
China with some key regions; enlarging the sales team with high efficiency; 
building up the modern logistics center and information management system for 
distributions. 
The customers are mostly the general hospital at Municipal level. The commercial 
distribution is the subordinate channel. Company has set up agencies or 
established the sales relationship in the key provinces in China. 
Products also go to the overseas markets. Mostly the products finally sell to the 
hospitals and the health institutions, also some government health departments 
will be the distributor to distribute the products, the biggest one can be the Red 
Cross of each country. This is the way company used in international market. 
Sxx Company exports products to Pakistan, Bulgaria, Peru, Thailand, Philippines 
and some eastern-European countries. Company now is trying to export to more 
European countries, enlarge the exporting quantity gradually and find more 
overseas agents. (Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year 
Development Plan, P7-P9) 
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When considering the exporting of plasma products to Finland, the Foreign Sales 
Corporation set up in Finland can be a good choice. There are lots of 
pharmaceuticals agents and middlemen that can cooperate with company, and 
also the government affiliated middlemen for example, the FRCBS. (Philip r. 
Cateora; Mary c. Gilly; John l. Graham, International marketing; P412 Foreign 
Sales Corporation) 
4.3.1   Distribution channel for plasma products 
Sxx Company has established the distribution system all around China with some 
key regions. There is modern logistics center and information management system 
for distributions of the plasma products. 
The main distribution channel is directly to the hospitals and through the 
middlemen and agents which works by the front-line sales staff. The customers 
are mostly the general hospitals at Municipal level. The commercial distribution is 
subordinate channel. Company has set up agencies and established the sales 
relationship in the key provinces for domestic market. 
For the overseas markets, Sxx Company exported products to Pakistan, Bulgaria, 
Peru, Thailand and Philippine, the exporting quantity is going to increase gradually. 
And company now is trying to find more professional overseas agents in European 
countries to expand the Europe market. 
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FIGURE 4. DISTRIBUTION CHANNELS OF PLASMA PRODUCTS 
This picture above directly shows the distribution channels the company used in 
China and abroad. The products go to the final patients from the company. 
There are two distribution channels being used for the company to sell the 
products, one is direct channel which company sell the products directly to the 
hospitals by the marketing department and logistics center of the company; 
another one is sell the products through the medical brokers and agents. 
(Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year Development Plan, P18) 
4.3.2 Direct channel 
Direct channel is a model in which no middleman involved and the products are 
sold from company to consumer directly. Plasma products are single-use, 
technically complex products, so the advantage of direct channel is that the 
products can be targeted for production, which better meet the market demands. 
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As direct channels without intermediate links, it can reduce distribution costs, 
control the initiative of price, and actively participate in the competition. But there 
are also challenges with direct channels, such as manufacturers make large 
investments into selling, which are costly, and the scope of sale is restricted. 
In the general situation, direct distribution channel is used for the domestic market 
(China), the front-line sales staffs go to the hospitals in the key region to promote 
the products. After dealing, the products will be transported to the target hospitals 
by the logistics center of the company as the contract. (Interview of vice general 
manager of Shanghai Xin-xing Medicine Co. Ltd.) 
4.3.3 Indirect channel 
Indirect channel is the product through of one or more distributors of the business 
to consumers; it is the main form of the sales. For those products export to the 
foreign countries, the middlemen can be the brokers’ agents or the government’s 
organizations, such as the National Ministry of Health or the Red Cross. 
The involvement of intermediaries, so reducing the number of transactions, 
distribution cost and time savings, prices can be lower.  Agents of brokers focus on 
expanding the scope and circulation sales, company can focus on production, it 
benefits the entire community of producers and consumers. 
Company takes advantage of other organizations’ domestic distribution channels 
in foreign countries and marketing experience to quickly bring products to foreign 
markets, which achieves good time efficiency. 
The indirect channels also reduce foreign exchange risk and a variety of export 
credit risks, the use of funds can be more secure. So considering Finnish market, 
indirect channel has more advantage compare with direct channel. 
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Its shortcomings are: because the involvement of intermediaries, so that 
communication between the manufacturers and consumers is inconvenient. 
(Interview of vice general manager of Shanghai Xin-xing Medicine Co. Ltd.) 
4.3.4 Management of distribution channel 
To construct a satisfactory distribution channel system is one key issue for the 
company to develop international markets. Manage the distribution channel 
system includes finding out potential middlemen who match company’s demand, 
motivating them in reasonable way, evaluating middlemen and controlling them. 
(Philip r. Cateora; Mary c. Gilly; John l. Graham, International marketing; P415 
Locating, Selecting, and Motivating Channel members) 
①  Select the channel members 
In general, a powerful manufacturer can easily find the suitable intermediaries, so 
does Sxx Company. As China’s designated production enterprise, the company 
has cooperated with some big medicine middlemen in China, most of the products 
export will through those agents.  
There are many factors affect the company chooses the channel members. It must 
reach the company's target market; geographical location must be advantageous; 
it should have market coverage which company needs; it has to be familiar with 
the sales objects and products; whether there is mutual promotion of products or 
competing products in the categories of goods that intermediaries is operating. 
Financial size, credit level, length of operating history and experience of the 
intermediaries must be rich; business facilities the intermediaries owned such as 
transportation, storage conditions, sample display equipment should be in a good 
situation; they should have a certain number of employees, the quality must be in 
a high level; it’s necessary that they have the sales ability and after sales service 
quality, management and information feedback capabilities have to be strength. 
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②  Motivate channel members 
The company not only selects the intermediaries, but also to motivate them to 
make them diligence. The factors and conditions of promoting dealers to enter the 
channels are components of incentive, but the company also pay attention to the 
criticism of intermediaries, criticism always put themselves in their shoes, and not 
only from the company’s own point of view. 
At the same time, company tried to avoid over-excitation (such as the conditions 
are too favorable to the intermediaries), and lack of incentives (such as the 
conditions are too harsh to intermediaries) both situation. 
③  Evaluate channel members 
In addition to select and encourage channel members, but also company must be 
regularly and objectively assessing their performance. If the performance of the 
channel is below the established standards, company needs to identify the main 
reasons, while also considering possible remedies. 
Sometimes when to give up or replace the intermediaries will lead to worse results, 
the company has to tolerate this unsatisfactory situation. When it will not be any 
worse result, company requires the intermediaries with poor performance to 
improve in the period of time, or its qualification will be canceled. 
④  Adjust sales channels 
Based on the actual situation and the performance of channel members, the 
company adjusted on the channel structure some times: changes in the number of 
channel members; changes in the quantity sales channels; and other changes in 
the distribution system. 
(Interview of vice general manager of Shanghai Xin-xing Medicine Co. Ltd.) 
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All the rules of managing distribution channels will also be used when products 
export to Finland. The middlemen whether in China or in Finland both will be 
managed with the same rule. 
4.3.5 Distribution in Finland 
Now there are two wholesalers in the nation-wide distribution of medicines in 
Finland. The hospitals can buy the company’s products from only one wholesaler 
because of the one-channel principle. When company considers penetration into 
Finnish market, they must adapt to Finnish way. 
Competitive bidding is the basic for hospital medicine purchasing, and "Public 
Procurement Act" stipulates that the public sector to follow strict procedural 
guidelines. No matter how the bidding is, the terms and conditions of the 
companies involved should be reasonable. 
Under normal circumstances, the hospital district holds a large procurement ring, 
which finds out all tenders of pharmaceutical procurement and it including 
procurement of medicine in the next two years. (Pharma Industry Finland, hospital 
medicines [ref. 8th September 2011]) 
The procurement of plasma products can also be done through the bidding, but 
there are many other ways for the distribution as well. 
Cooperating with Finnish Red Cross can be one choice, although now they have 
the partner agreement with Octapharma plasma Inc. to provide the Finnish plasma, 
but other company can direct provide their products for FRC to distribute the 
products to the hospitals. 
Finding out some big Finnish medicine distribution agents can also expand the 
market in Finland. The agents are normally high experienced, and have the mature 
sales network in Finland, so that the sale of products can be efficiently. 
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Sometimes, there are some major government Ministries of Health cooperation 
projects between the countries, this is also a good opportunity to distribute the 
products, and Sxx Company is the country's designated production enterprise, so 
this method can be considered. (Pharma Industry Finland, pharmaceutical 
distribution [ref. 4th August 2011]) 
4.4 Promotion 
With the growing market demands over the past few years, blood products have 
changed from a buyer's market to seller's market. In this condition, the blood 
products manufacturers would not do large promotion activities to promote the 
sales, but to promote the brand to improve the brand image. 
Sales promotion is to motivate consumer purchases and develop the effectiveness 
of middlemen. Promotion choices available for B-to-B market are not as extensive 
as those used in the consumer markets. The ways that can be utilized mostly are 
price-reductions, product sampling and trade fairs. Among these three choices, 
trade fairs are by far the mostly widely used sales promotion for B-to-B marketers. 
(Philip r. Cateora; Mary c. Gilly; John l. Graham, International marketing; P464 
Sales Promotions in International Markets) 
Publicizing the new products to hospitals and the middlemen which competitors 
don’t have is the first choice for the company to do. Now company has 3 new 
products in research, so it’s very important to get the clinical validate approval as 
soon as possible. 
Sxx company uses also some other methods for promotion when get into the 
international market. The first method is to send the samples products to the 
distributors or the hospitals in target market with detailed description letter and 
Insurance Statement. After using or evaluating of the samples, the hospitals or 
distributors can know the advantage of buying the products from the company. 
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The second method is to participate in some large medicine fairs to show the 
products and build the image of the company. Sometimes, the company even can 
be the sponsorship of special events to improve the brand image, especially some 
international charity activities which the products of the company can be used. 
This way can be used both in China and in Finland. 
In domestic market, the first-line marketing staffs do the promotion to the hospital 
by regularly sending the newest information of the products to the drug 
administration department of the hospitals. And also they collect the information 
about the competitors, such as the price and the species of products. 
For the promotion of exporting products, company sometimes draw support of 
Chinese embassies, reached an agreement with target place government health 
departments to import the products of the company. When consider Finnish market, 
get the cooperation or partner relationship with FRCBS can help a lot for the 
marketing of company in Finland. 
(Interview of vice general manager of Shanghai Xin-xing Medicine Co. Ltd.) 
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4.5    SWOT Analysis of the company 
Strengths Weaknesses 
1. Company is the China's designated 
production enterprise, while pharmaceutical 
sales network covering the whole country and 
some other countries, guaranteed product 
quality and sales; 
2. The company has a post-doctoral 
research station, with GMP certificate from 
SFDA China and Asia-class level blood 
products manufacturing plant, which is strong 
in research and has the advanced production 
technology. 
1. Now company has only 2 plasma 
collection stations, lack of the raw material for 
production; 
2. Less of incremental capital accumulation 
and asset, compare with the enterprises in the 
industry, the ability of fund operations of the 
company is at the lower level. 
3. Company now doesn’t have the EU-GMP 
certificate. 
Opportunities Threats 
1. Plasma products as a blood substitute, 
have broad market prospects; 
2. This approximately $ 10 billion global 
market provides an attractive space for the 
enterprises, who master blood products 
production technology; 
3. With further improvement of people's 
living standards and medical conditions 
demand further improved, high demand for 
plasma products will gradually increase, SXX 
company will get good opportunities for 
development and external environment; 
1.     China National price departments have 
substantially and continuously adjusted of 
medicine prices, related policies have been put 
forward, which brings a great deal of influence for 
profitability of the industry; 
2. The international pharmaceutical 
industry, especially in blood products industry is 
highly competitive. 
FIGURE 5. SWOT ANALYZE OF THE COMPANY 
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5.  FINLAND 
Year of EU entry 1995 
Political system Republic 
Capital city Helsinki 
Total area 338 000 km² 
Population 5.3 million 
Currency Euro 
Official languages Finnish, Swedish 
FIGURE 6. OVERVIEW OF FINLAND 
(EUROPA website, EUROPA > About the EU > Countries > Member countries > 
Finland [ref. 20th August 2011]) 
5.1   General information about Finland 
Finland is located in northern Europe. Bordering of Sweden, Norway and Russia, 
the Gulf of Finland to the south, the west is Gulf of Bothnia. Finland has coastline 
of 1100 km. Terrain is from north to south. Area of inland water area accounting for 
10% of the country, there are islands of about 179,000, about 188,000 lakes, 
which has the name "country of thousand lakes". 1 / 3 of the national land are in 
the Arctic Circle. It’s a temperate maritime climate. Average temperature in winter -
14 ℃ -3 ℃, summer 13 ℃ -17 ℃, the average annual rainfall 600 mm. 
 
 
PICTURE 5. FINLAND MAP 
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The earliest residents of the Finnish are Lapps, so that Finland is also known as 
Lapland. The latter half of the twelfth century Finland was by the Swedish rule. 
After 1809 Russia and Sweden war, Finland belong to Russia and became the 
Grand Duchy. December 1917 the Republic of Finland declared independence. 
Finland is a country of gender equality. Finnish women got the right to vote as 
early as 1906 and other equal political rights with men. Today, many Finnish 
women are in key positions in politics: in 2003 parliamentary election, 76 women 
were elected as members. There are 18 ministers in the government 8 of them are 
female, and even the President of the country is also a woman. 
Education of Finland is highly developed. Compulsory education system carried 
out since 1921. Implement of nine years of consistent system of compulsory, free 
education in the country since 1980. In 2003 education budget for 5.786 billion 
euros, this is 15.7% of the total government budget. 
Finland now has an advanced and modern economy system; especially the 
telecommunications equipment industry brings about huge economic income, for 
example, Nokia is the leader in mobile phone market. Finland has high forest 
coverage, so that the paper making industry is the main industry in Finland as well. 
(Baidu website, Introduction of Finland [ref. 20th August 2011]) 
5.2    Finnish economy 
Since 2010, with the gradual recovery and developed of global economy after 
2009 global financial crisis. Effect of Finnish government’s economic stimulus 
measures appearing, Finnish economic recovery has been strengthen, economy 
had continued to show solid growth. 
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According to preliminary data by Finland Statistics center, after the sharp 
economic downturn 8.2% in 2009, Finland 2010 GDP reached 180 billion euros, 
which is an increase of 3.1%. Although the first quarter fell by 0.8%, but the 
second and third quarters of economic growth were 3.7% and 3%, after entering 
the fourth quarter, growth accelerated, October to December growth rate was 
5.5%, 7.5% and 7.2%. As a small open economy, Finland economic growth 
remains highly dependent on world economic recovery and trends. (Travel 
Document Systems, Finland Europe, ECONOMY [ref. 22th August 2011]) 
Benefit from the Finnish government food tax reduction and other economic 
stimulus measures, consumption continued the growth momentum since the 
second half of 2009, 2.6% annual growth in private consumption, public 
consumption growth being 0.4%. 
Biopharmaceutical industry which includes the plasma products is one of Finland's 
core competencies, its annual market sales as high as 16 billion euros. 
Online shopping has become a new bright spot in Finland public consumption, the 
2010 expenditure of nearly 100 million euros, mainly consumer items, including 
tourism, transportation, gaming, accommodation, electronic products and clothing. 
Consumer confidence index continues to rise, reached 23.0 in September 2010, 
which is a high record. Investment growth of 0.8%, which benefits from substantial 
increase in investment in housing construction, and private investment increased 
by 3.5%. 
 
 
 
38 
 
In the situation of international markets getting warmer and warmer, Finland's 
foreign trade resumes growth, import and export of one-month continued to 
increase and improve. According to Finnish customs statistics, total foreign trade 
of Finland throughout the year 2010 was € 103.9 billion, up 17 percent, with 
exports 52.4 billion euros, up 16%; imports 51.5 billion euros, an increase of 18%. 
Export growth is mainly affected by chemical, metal and machinery manufacturing 
industry to promote, the growth of major imported commodities such as crude oil, 
petroleum products and concentrates, etc. 
2010, Finland's top three trading partners were Russia, Germany and Sweden, the 
top three export destinations being Sweden, Germany, Russia. Finnish trade with 
China was € 64.7 billion, up 21 percent over the previous year; China is Finland's 
fifth largest trading partner, just after Netherlands. Finnish imports from China 
were € 3.78 billion, which increased 9%, exports to China were € 2.69 billion, an 
increase of 45% in 2010. 
In addition, annual foreign direct investment to Finland was 35.2 billion euros and 
foreign investment flows was -3.7 million euros which was negative. That shows 
that foreign enterprises interest in investing Finland has reduced, the scale of 
investment has also been shrink. (ifeng.com, 2010 Finland economy situation [ref. 
23th August 2011]) 
5.2.1    Finnish business culture 
In Finland to become a successful entrepreneur, you have to be familiar with the 
rules of the Finnish business culture, attitudes and habits. There are lots of 
characteristics of the Finnish society which use Europe-style and the individual as 
the center. 
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Finns are good at rational use of time. They have strict timetables or other 
scheduling, but also want others to comply with the time. Finns are relatively 
cautious, before negotiation they will collect background information in advance, 
but can make a decision quickly. 
They distribute powers and responsibilities flexibly. Work style of Finns is 
consistent with their way of how to think. Therefore, they sometimes avoid some 
unfamiliar ways of doing things. 
In Finnish society, everyone is equal. Sense of distance caused by the power is 
not strong; people usually address each other directly by first name. Men and 
women are equal. Everyone are willing to settle disputes through negotiation, all 
parties are satisfied for the results. 
When negotiating with Finns, understand your own value, but do not be 
complacent, modest is better; do not expect there will be feedback on your 
comments; try to stop from time to time in the conversation, relax, and treat it as a 
positive thing; if there is opportunity to try to go to sauna. Afterwards you can go 
out together with a cup of cold drink. 
To achieve common goals when doing business in Finland, you should have clear 
objectives, clear process, and clear division of responsibilities; trust the wisdom 
and perseverance of others, let them solve the problem themselves. Finns do not 
like over-regulation. They like to solve their problems by their own. 
Finns like to talk to the people has a good sense of humor, cultural differences can 
be discussed. The last thing to remember is demonstrate a genuine interest in 
Finnish culture. 
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When doing business with Finns, you have to be familiar with Finland and the 
Finnish products, at least to know Nokia phones. Another is that personal dignity is 
very important for Finns. Although the Finns do fast decision-making process, but 
once a decision becomes difficult to change, unless there are good reasons. 
(Communicaid Group Ltd. 2009, Finnish Social and Business Culture) 
5.3   Finnish Healthcare sector 
Finnish government enacted the "disease Health Insurance Law" in 1963 and 
provides for implementation and Management by the Ministry of Social Affairs and 
Health. Objects to enjoy health insurance for people are citizens or who have 
obtained the nationality of the immigrants. There is no nation, age, income and 
occupational differences. 
With local healthcare authorities, people who enjoy health insurance all have an 
insurance card, so that they can enjoy free or relief medical treatment care. Many 
public Finnish welfare organizations were operated by the state or local 
government. 80% of welfare facilities, equipment cost are contributed by the state 
and local government, and the remaining 20% self-financing by the operator. 
5 provinces and one autonomous region have set up provincial Department of 
Social Affairs and Health, which is responsible for managing and coordinating 
provincial health care services and hospital management issues. Cities, towns, 
communities also have the appropriate health authorities, responsible for local 
health care. 
Small hospitals get the support of each other and also from university hospitals 
and central hospitals. Urban hospitals and rural hospitals co-ordinated and 
common development, thus it ensure the residents of the country all has rights to 
enjoy the health care system, wherever you live. 
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FIGURE 7. ORGANIZATIONAL CHART OF HEALTHCARE SYSTEM  
An important feature of Finnish health service system is the focus of universal 
health care and prevention, primary health care network throughout the country to 
ensure that the urban and rural residents have equal access to health care, 
prevention and care services. 
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There are also several agencies and institutions in the social welfare and health 
care sector that work for research, development, statistical and supervising 
functions. These agencies and institutions all cooperate with Ministry of Social 
Affairs and Health. These agencies and institutions are: 
• National Public Health Institute (KTL) 
• National Agency for Medicines (LL) 
• Centre for Pharmacotherapy Development (ROHTO) 
• National Research and Development Centre for Welfare 
and Health (Stakes) 
• National Product Control Agency for Welfare and Health 
(STTV) 
• National Authority for Medicolegal Affairs (TEO) 
• Radiation and Nuclear Safety Authority (STUK) 
• Insurance Supervisory Authority (VVV) 
(Brochures of the Ministry of Social Affairs and Health 2004: 11, Health Care in 
Finland; P6-P7) 
5.4   Competition of plasma products in Finland 
Plasma products each year could save thousands of lives in Finland, it greatly 
improved life expectancy and improving quality of life of dying patients, and 
support complex medical and surgical procedures. 
Biotechnology is in the same statue as information technology. The government of 
Finland placed it on the highest priority of high-tech programs. Since the 1980s, 
the Finnish government started to pay attention to the investment of biotechnology 
science industry. In early 1990s, the government of Finland has started to support 
the development of biotechnology science and technology strategy, and increase 
investment in life science research. 
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Nowadays, the investment of Finnish biotechnology science industry in R&D is 
about 200 million euros each year, equivalent to 13% of total public R&D 
investment. 
Plasma products industry as one important part of the biotechnology science also 
is treated as major program by the Finnish government. Under this condition, the 
hospitals and healthcare centers in Finland mostly use the local Finnish plasma 
products. So the Finnish brand takes the highest market share in Finland. 
Finnish Red Cross Blood Service is the biggest nationwide blood products provider. 
Since 2010, all Finnish plasma collected will be delivered to Octapharma plasma 
Inc. for production with the partnership agreement. After that Blood Service 
supplies medical plasma products to hospitals and pharmacies based on their 
orders. (Finnish Red Cross Blood Service Annual Report 2010, P10) 
Other world leading plasma products manufactures occupy a certain market share 
in Finland as well, such as: Talecris, CSL Behring, Baxter and so on. These foreign 
companies normally sell their products through the brokers to the hospitals, so 
there is the challenge to the Finnish local brands. But now the plasma products 
market is seller's market, so compared to that when it was buyer's market years’ 
ago, there is less intense competition in the market. (Research Report of Produce 
and Sale and Investment Analysis on Chinese Blood Products Industry 2008, 
P136) 
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6.   THE MARKETING RESEARCH 
The implementation of the marketing research of this study was done in May 2011, 
the time was planned before the study by discussing with the supervisor, and the 
questions in the survey-questionnaire were decided at the same time as well. 
Language for the questionnaire was English. 
20 hospitals were taken into research include 5 university hospitals, 7 central 
hospitals and 8 local hospitals. Hospitals’ contact information was found from the 
Finnish yellow pages and some hospitals own websites. 
6.1   Research methods 
Both quantitative and qualitative methods were used as the research methods in 
this research. The subjects for quantitative research method are normally a large 
group. In this study target organizations were all the hospitals in Finland. Those 20 
hospitals which were selected into study are mostly the national hospitals or main 
hospitals in that area. 
Two interviews were used as the qualitative method part. The first interview was 
done with one director of FRCBS by e-mail in May, the second was done with the 
vice general manager of the case company in July. The purpose of the interview is 
to get more information of the biggest distributor (FRCBS) of plasma products in 
Finland, and also to know more about the operation of the case company. 
6.2   Research problem and goal 
The client of this study was Shanghai Xin-xing Medicine Co. Ltd. which 
manufactures various kinds of plasma products. The goal of the study is to clarify 
the method of marketing Chinese plasma products in Finland, so that the company 
could get more information about Finnish market what the company should do to 
expand into the new market. 
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The main research problem in the study is: 
- What is the method of marketing Chinese plasma products in Finland? 
There are also some sub questions of the study are: 
-Are there now Chinese plasma products used in Finland? 
-What factors affect the hospitals when they select plasma products? 
-What is the competitive advantage of Chinese plasma products? 
-Is there possibility that the case company could cooperate with FRCBS? 
-Are the hospitals in Finland planning to use Chinese plasma products in the future? 
 
6.3   Validity and reliability of the research 
The marketing research of marketing Chinese plasma products in Finland is valid 
and reliable in some certain question, which got same answers of the 5 responses. 
But consider the fact situation that some of the answers weren’t received back it 
may cause by language effects. The research measures what it is supposed to 
measure. 
The questionnaire was sent to 20 main hospitals in Finland which 5 hospitals gave 
the responses on time. So the return rate of this study is 25%. Response rate 
could have been higher if questionnaire has Finnish version. 
Low response rate were caused by language barriers mostly, because the 
questionnaire was only done in English version. And another reason is the scope 
of the research was relatively small, only 20 hospitals were taken into the research. 
The questionnaire is given in the appendices part in the end of the thesis, it is easy 
to see the questionnaire is clearly structured and easy to follow, and there are no 
confusing questions included. 
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7.  ANALYSIS OF ENVIRONMENTAL FACTORS IN FINNISH 
MARKET 
Market opportunity exists in all aspects of social life which is varied. But for the 
enterprise, the large number of market opportunity, only a small part has practical 
significance. 
Two factors affect the marketing metod, one is product, and another is the 
environment. Through study for these two factors and other related factors, the 
company can better grasp the market. (Philip r. Cateora; Mary c. Gilly; John l. 
Graham, International marketing; P11 the international marketing task) 
7.1 Product factors 
The plasma products is made of the human plasma, and currently there are more 
than ten kinds of the plasma products, such as human serum albumin which is 
mainly used to increase blood volume, maintain the plasma colloid osmotic 
pressure, transport and supply nutrition; human immune globulin which is used to 
treat the indication of immunoglobulin deficiency; and human prothrombin complex 
which is used to treat the indication of factor II, VII, IX, X deficiency. 
By studying the result from the marketing research, now species of products that 
Finnish hospitals are using are approximate Human Albumin, Human 
Immunoglobulin, Intramuscular, Human Tetanus Immunoglobulin, Human Hepatitis 
B Immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection, and 
Human Coagulation Factor Ⅷ. (Result of the Marketing Research) 
Products mentioned above are all Sxx company now can manufacture, this will be 
an advantage for the company to expand the market. 
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Distribution channels for the plasma products sales is through the medical agents, 
they get the products from the manufacturers and sell the products to the hospitals 
or healthcare centers. Most foreign brands sell their products in that way. On the 
other hand, some products are distributed from the Finnish Red Cross to reach the 
hospitals, basically those products are manufactured by Octapharma plasma Inc. 
which uses Finnish plasma. 
Hospitals often use to import the products is through the Finnish Red Cross and 
very little get products from the medical agents. This is because the FRC is the 
nationwide plasma products provider and has the network covering whole Finland. 
The quality and delivery time of products from the FRC can be guaranteed. 
Quality and the time of deliver products to be considered for most of the hospitals, 
but there is also another important factor which is price of the products. Shortage 
of plasma products leads to the price rising, the market can change from the buys’ 
market to sells’ market. 
If compare the price with the products manufactured in European countries, the 
price is another competitive advantage for the company, it’s all because of the low 
labor cost and the government support. 
7.2 Environment factors 
Environmental factors also affecting the method of marketing the products, and 
this factor is more complex. But many companies get good performance in the 
market through intervention of environmental factors. (Philip r. Cateora; Mary c. 
Gilly; John l. Graham, International marketing, P10) 
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Macro-Environment 
Population of Finland is approximate 5.3 million. There is certain population of 
ageing which is a major problem for the Finnish government to face. But at the 
same time, there shows another market demand for the plasma that is the elderly 
homes. 
Finland is well-known high-welfare country. People from birth have enjoyed the 
health benefits and subsidies from government of Finland. When people get sick 
and go to the hospital or after they retired and go to the home for the old people, 
they don’t need to worry about the cost. This social situation refers that the Finnish 
hospitals also get the subsidies from government, so that they can reduce the 
financial pressure. (Brochures of the Ministry of Social Affairs and Health 2004: 11, 
Health Care in Finland, P5) 
Pharmaceutical Administration Department of Finland is National Ministry of Health 
is responsible for medical supervision. In Finland, you need to obtain permission 
from this agency to carry out the production of pharmaceutical products, import, 
wholesale and retail. 
Pharmaceutical Administration accepts the public complaints for pharmaceutical 
products, and they also supervise and inspect the quality of medical products and 
raw materials quality. 
"Medical Law" stipulates that it is forbidden to do falsify or exaggerate publicize in 
the composition of the product, raw materials and efficacy. If a violation in the 
sales process in the above provisions, the Board will order to stop selling that 
medicine and there will be the punishment of relevant personnel. (Brochures of the 
Ministry of Social Affairs and Health 2004: 11, Health Care in Finland, P20) 
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Micro-Environment 
Plasma collection of blood services faces enormous challenges worldwide, now 
the hospitals need to provide adequate plasma products to meet the needs of 
patients, which means there is big market demand for plasma products. 
Shortage of plasma products is an indisputable fact. Sometimes there might have 
some illegal channels for the distribution for the plasma products which is the 
black market. To solve this problem, Finland has formulated strict laws to 
effectively regulate the medicine market. 
Suppliers’ analysis 
The changes of resources (Raw materials, auxiliary materials, equipment, energy, 
labor, capital, etc.) directly affect to enterprise product output, quality and profits, 
thus affecting the corporate marketing plan and marketing goals. So the stable 
delivery of resources can make the company complete the goal better.  
Company now has two own subsidiary stations of sole plasma collection, so the 
raw material plasma delivery can be always stable. Production equipment are all 
import from foreign large enterprises, and the company regularly check equipment 
operating conditions, to keep them running well. 
Now it’s necessary for the company to build more stains of plasma collection to 
keep plenty supply of raw material, and improve the standards to meet the Finnish 
or European qualification.  
(Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year Development Plan, P5) 
 
 
 
 
 
50 
 
Enterprise internal department analysis 
Work and coordination of various functional departments within the enterprise, can 
directly affect the entire marketing activities. When company in developing 
marketing plans, marketing activities, and executives can coordinate and handle 
the contradictions and relationships among the various departments very well. 
Each department can effectively communicate, coordinate, and create a favorable 
business environment and make the greatest efforts to achieve marketing 
objectives. (Shanghai Xin-xing Medicine Co. Ltd. 12th Five-Year Development 
Plan, P22) 
Marketing intermediaries’ analysis 
Company chose qualified intermediaries and established a good working 
relationship with them. Understanding and analysis intermediaries’ business 
activities, and take some incentive measures to promote their business activities. 
There are also advertising media operating companies, market research 
companies, marketing consulting companies, financial companies and other 
organizations which provide professional services for Sxx Company. They help the 
company to establish market positioning, marketing efforts, provided to facilitate 
the activities. 
The company has its own logistics center but normally it’s used for the domestic 
marketing activities. So for the export marketing, company has signed contract 
with several big warehousing companies and transportation companies to export 
the products to the target market. To find out some professional blood products 
logistics company can be used for entering Finnish market when considering 
deliver products to Finland in low risky situation. 
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Financial Analysis 
The primary function of financial institutions (banks, trust companies and 
insurance companies) is to provide finance and insurance services for the 
company’s marketing activities. Now the company has the cooperation relationship 
with some big national banks, and it’s the country's designated production 
company so company has the high credibility. (Interview of vice general manager 
of Shanghai Xin-xing Medicine Co. Ltd.) 
Competitors Analysis 
There are certain numbers of competitors in the Finnish market, such as 
Octapharma plasma Inc., Talecris, CSL Behring, Baxter, Bayer and so on , and 
they are all the large plasma products manufacturers even the world marketing 
leader. So there is really intense competition. 
Those enterprises are mostly European companies, they have many advantages 
compare with the case company, no matter the plasma storage, enterprise-scale 
and distribution channels, they are much better than Sxx Company.  
Now the basic advantage the company can grasp is the price. And if the company 
can corporate with the FRCBS, then the products from China can keep stable 
delivery to Finnish market. This can be the best way for the company to enter 
Finnish market by first step. (Research Report of Produce and Sale and 
Investment Analysis on Chinese Blood Products Industry 2008, P136) 
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8. MARKET ANALYSIS FOR CHINESE PLASMA PRODUCTS IN 
FINLAND 
Based on the given results of the questionnaire send to the 20 hospitals, there 
were 5 hospitals gave the response to the survey, so the return rate is 25%. The 
reason for this return rate which is not so high might be the language effect. 
There are some charts made from the results of the question in the questionnaire, 
which can be helpful to evaluate the future market in Finland. 
 
FIGURE 8. PRODUCTS HAVE BEEN USING NOW 
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From figure 5 one is able to see that the product Human Hepatitis B 
Immunoglobulin has been used in most of the hospitals, and the Human 
Immunoglobulin, Intramuscular and Human Coagulation Factor VIII are also widely 
used than other products. Some other products which now is under research level 
of the company not been used in Finnish hospital yet, such as Human Prothrombin 
Complex and Surgical Lyophilized Fibrin Sealant. 
Combination of the aforementioned, the 6 kind plasma products now have been 
used in Finnish hospitals are all those products which the company can 
manufacture. In addition, in order to make the company more competitive, 
research strength should be an advantage to accelerate the development of new 
products. 
 
FIGURE 9. FACTORS THAT AFFECT PRODUCT SELECTION 
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The above figure shows that the factors that affect the hospitals when they choose 
the plasma products. Quality always has been taken into consider at the first place, 
all the 5 hospitals who gave response thought quality is the most important for 
them. Then 3 out of 5 respondents thought the delivery time is the second factor 
affect. After those two main factors, price is also important for some hospitals, 
especially the private hospitals which don’t have so much founds compare with the 
national hospitals. 
At the same time it’s easy to see that for this special biopharmaceutical product, 
the promotion cannot be of much effect. So the company can handle the price 
advantage to provide the products with the same quality but a lower price. 
 
FIGURE 10. DISTRIBUTION CHANNEL NOW BEEN USED 
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This chart shows a clear situation that all the five hospitals who answered the 
questionnaire, their distribution channel to get the plasma products are all from the 
Finnish Red Cross. It is clear that the FRC blood service has a large effect on 
hospitals in Finland, and their network covered nationwide. On the other hand, 
because of the partnership contract, Octapharma plasma Inc.’s product can be 
most competitive in Finnish market. 
There is another thing need to mention is that one answer from one of the 
directors from FRCBS, when asked “If it is possible to use Chinese blood products 
in the future?” he answered “This question is not so relevant for FRCBS, but of 
course some of our customers might be interested in to use Chinese blood 
products.” 
It also explains there should be some opportunity for the Chinese plasma products 
in Finnish market, and even it can be the cooperation program with the FRCBS. 
8.1 The risk of plasma products import 
Plasma product as one of the special products, most of the products should be 
stored in a low temperatures environment, and the transportation must be also in 
the same condition. 
The most rapid way of transportation should be as fast as possible. To shorten the 
transport time, but the safety should be taken into consideration at the same time.  
There is also the requirement for the seasons of the year when transport the 
products. It’s best to use refrigerated transport method and avoid delivery of 
products during summer. If it is in winter, transport should be taken to prevent 
freezing of product. 
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FIGURE 11. RISKY OF IMPORT FROM CHINA 
Above figure is one question in the questionnaire sent to hospitals, most of 
hospitals though it’s risky to import the product from China. The factor that affects 
this answer can be the logistics distance. The air transport distance from Beijing 
the capital city of China to Helsinki is approximately 6300 km, and this is the 
fastest way to deliver the products but it also costs more when compared with 
shipping and road transportation. 
The long distance the higher risky level it has, that is why some hospitals thought it 
is risky, but there are also some hospitals which thought that it won’t affect so 
much if everything can be done in accordance with the strict requirements. 
If Sxx Company would cooperate with FRCBS, the products will be transported to 
Finnish Red Cross and after that it will delivered to hospitals. So if the company, 
FRCBS and the hospitals can choose the best logistics method, the transport risk 
can be reduced to very low. 
 
57 
 
8.2 Market needs of plasma products 
 
FIGURE 12. BLOOD AND CELL PRODUCTS FOR HOSPITALS 2007-2010 
This figure is made based on data collected from the Finnish Red Cross Annual 
Report 2009 and 2010. It shows the quantity of blood and cell products all Finnish 
hospitals used over the past few years. 
From the chart it is clear to see that except the frozen plasma and plasma 
products from Octaplas, number of all other products used in the past few years 
(2007-2010) has remained stable. The use of frozen plasma got a sharp decline 
after 2007, at the same time, use of plasma products increased sharply. The 
reason for this phenomenon is that with the demand of plasma products from that 
time began, the FRC basically put all the frozen plasma into Octaplsa Inc.’s 
production to manufacture the plasma products. (Finnish Red Cross Blood Service 
Annual Report 2009 and 2010) 
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8.3 Export of Chinese plasma products prospects analysis 
International market is a wide market, there are two different situations: one hand 
the developed countries in the context of meeting their own needs and also 
occupy the largest share to export products to developing countries; on the other 
hand, most developing countries are unable to produce blood(plasma) products, 
they had to rely on imports. 
Blood products in the international market, Europe accounted for 40% of the share, 
the United States and the North American continent is about 41%, Asia-Pacific 
continent is 8%, Japan 5%, 6% for the rest of the Indian subcontinent and other 
markets. 
As the relatively high standard of plasma products of the market in Europe, North 
America, Japan and other countries and regions, such products from China and 
other developing countries is difficult to access. Therefore, China's plasma 
products exports are more to international non-mainstream market-oriented, such 
as Southeast Asia, the Middle East, Indian subcontinent, Mexico and Africa. 
With the increasing living standards in developed countries and development of 
the economy in developing countries, the need for plasma products will gradually 
expand. But at present, compare with other big countries, China's plasma products 
export volume is still very low. The main reason for this situation is that most 
plasma product enterprises in China have not yet obtained the recognized quality 
certification from the importing countries. 
So that the company should intensify its work in this area, based on the GMP 
certification in China, strive to achieve the internationally or developed countries’ 
recognized quality certification, most important is the European Union EU-GMP 
which is used in Finland, WHO-GMP and U.S. FDA-GMP standard. 
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Because China's large population base, which means that the reserves of raw 
materials plasma is also a large volume, once China’s plasma products achieve 
such certification, it can be certain competitive in the developed countries’ market. 
(Research Report of Produce and Sale and Investment Analysis on China Blood 
Products Industry 2008, P185) 
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9. RESEARCH RESULTS: ADAPTATION IN FINNISH MARKETS 
The main conclusion of this study is that recently there is no market for the 
Chinese plasma products in Finnish market, but in the future years, there is certain 
market for Chinese plasma products in Finland.  
By analyzing the marketing mix (4Ps), consider for “place” factor. The best method 
Sxx Company can use to expand Finnish market is to adapt the Finnish way, 
which means if they would cooperate with FRCBS to distribute the products can 
be the best choice. 
The main reason is the market demand of plasma products is continue increasing 
in Finland and the customers of FRCBS may wish to use the Chinese plasma 
products. But considering the “product” factor, company has no WHO-GMP or EU-
GMP certificate now, but it is possible to get them in the following years. After that 
the plasma products from China can take market share in Finland as well. 
In “promotion” factor, if the company wants to get into Finnish market in simple way, 
select a good way for promotion is also important. They may consider how to build 
their brand image in Finland. Especially leave an impression to the FRCBS which 
can make them think it is worth to cooperate with Sxx Company. For example, the 
company should have some ideas when doing the promotion that how to makes 
the Finnish customers sure that it’s not risky to import plasma products from China. 
At last, in “price” factor, considering the past few years, exchange rate between 
Euro and Chinese currency RMB continued to depreciate gradually, so choose the 
suitable pricing method is necessary for the company as well. 
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In the end the company itself and their marketing methods will decide that if they 
are able to expand into the Finnish market to meet the demands. If the company is 
going to focus on their best advantage to meet the marketing goal, there is big 
possibility to increase the market share and their sales as well. If they successfully 
achieve the market share in Finland, they will need sufficient raw material plasma 
for production to meet the growing market demand. 
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10. SUMMARY  
There were several problems met during the research. The first was that what 
target group should be taken into the research, because there are so many 
hospitals and healthcare centers in Finland. After visiting the local healthcare 
center in Seinäjoki, the target group was decide to be the main hospitals of 
different area in Finland, because the information got from the healthcare center 
was their plasma products were all provided by the local hospitals. 
The second problem was that the hospitals normally not publish their e-mails on 
their website, only thing can be found was the telephone numbers, so it’s not 
possible to find the contact e-mails of the hospitals, even FRCBS would not 
provide this information because it can be business secret. The only way to get the 
e-mail address was to call the hospitals one by one, but at the same time the third 
problem came which was the language barriers, most of them don’t speak English. 
After all problems were solved, the study continued. 
Because the return rate of survey-questionnaire was 25% which can be higher if 
there is Finnish version. So the data in this study is validity and reliability in some 
certain questions, but it can still be useful reference for Sxx Company when they 
consider get into the Finnish market. 
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APPENDICES 
APPENDIX 1. 
Marketing Research                                               
Dear receivers, 
I am the student of Seinäjoki University of Applied Sciences, now I am working on 
my bachelor’s thesis. The purpose of my study is to clarify the future market of the 
Chinese plasma products in Finland. The study will show the situation on the 
plasma products markets in Finland. 
You may send the fulfilled questionnaire to my e-mail address: 
ydc2lkj@hotmail.com or Dongchuan.Ye@seamk.fi. If there is any question you 
may also call me at +358466427880. 
I hope to get the survey in as soon as possible but at latest at (time) 
Thanks a lot for your cooperation and look forward to hear from you soon. 
 
With Best Regards, 
 
Ye Dongchuan 
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APPENDIX 2. 
Survey/Questionnaire 
1. What plasma products have been used in the hospital/healthcare center 
now? 
□ Human Albumin 
□ Human Immunoglobulin, Intramuscular 
□ Human Tetanus Immunoglobulin 
□ Human Hepatitis B Immunoglobulin 
□ Human Immunoglobulin (pH4) for Intravenous Injection 
□ Human Coagulation Factor Ⅷ 
□ Human Prothrombin Complex 
□ Surgical Lyophilized Fibrin Sealant, 
□ Human Thrombin, Lyophilized for external use 
□ Others (if you choose this, please write what is the product)  
 
2. The hospital uses the Finnish brand plasma products or foreign brand? 
□ Finnish brand 
□ European brand 
□ Chinese brand 
□ American brand 
3. What brand(s) of plasma products have been used? 
———————————————————————————————— 
———————————————————————————————— 
4. If the hospital is now using plasma products imported from China? 
□ Yes 
□ No 
 
5. Are you planning to use plasma products from China? 
□ Yes 
□ No 
6. How risky you consider during the logistics to import the products from 
China? 
□ Very risky 
□ Risky 
□ A little risky, but not affect so much 
□ Not at all risky 
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7. What affects mostly when you choose the plasma products? (You can 
choose two) 
□ Quality 
□ Price 
□ Time of delivery products 
□ The promotion of some medical brand 
8. What is the distribution channel the hospital uses to import the products? 
(fill this if the hospital use the foreign brand products) 
□ Finnish Red Cross 
□ Wholesalers 
□ Manufactures 
□ Others (Please write what is it)  
—————————————————————————————— 
9．Other comments 
—————————————————————————————— 
—————————————————————————————— 
—————————————————————————————— 
 
 
